世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

NA消化不良治療薬市場-2030年までの産業動向と予測


NA Dyspepsia Drug Market - Industry Trends and Forecast to 2030

北米の消化不良薬市場は、2022年の351,924.80千米ドルから2030年には539,245.09千米ドルに達し、2023年から2030年の予測期間中に年平均成長率5.6％で成長すると予測される。 市場細分化： 北米の消化不良薬市... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
Data Bridge Market Research
データブリッジマーケットリサーチ 		2023年5月1日 US$3,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		272 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

北米の消化不良薬市場は、2022年の351,924.80千米ドルから2030年には539,245.09千米ドルに達し、2023年から2030年の予測期間中に年平均成長率5.6％で成長すると予測される。

市場細分化：
北米の消化不良薬市場：タイプ別（器質性消化不良、非潰瘍性消化不良、薬剤性消化不良、その他）、治療タイプ別（投薬、手術）、薬剤タイプ別（ブランド薬、ジェネリック医薬品）、処方薬別（処方薬なし、処方薬）、投与経路（経口剤、注射剤）、性別（男性、女性）、エンドユーザー（病院、診療所、在宅医療現場、専門クリニック、外来手術センター、学術・政府研究機関、その他）、流通チャネル（直接入札、小売販売）、国（U.S.,産業動向と2030年までの予測


北米の消化不良治療薬市場ダイナミクスの概要

促進要因
- 消化不良の有病率の増加

抑制

- 消化不良に使用される薬剤の副作用の可能性

機会

- 高齢化人口の増加


市場のプレーヤー

北米の消化不良薬市場に参入している主な市場プレーヤーを以下に挙げる：

- アボット
- バイエル
- カディラ・ファーマシューティカルズ
- サノフィ
- ルパン
- ペリゴ・カンパニー・ピーエルシー
- レキットベンキーザー
- アストラゼネカ
- プロクター・アンド・ギャンブル
- 大塚製薬
- その他



ページTOPに戻る


目次

TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE NORTH AMERICA DYSPEPSIA DRUG MARKET 84
1.4 CURRENCY AND PRICING 86
1.5 LIMITATIONS 86
1.6 MARKETS COVERED 86
2 MARKET SEGMENTATION 90
2.1 MARKETS COVERED 90
2.2 GEOGRAPHICAL SCOPE 91
2.3 YEARS CONSIDERED FOR THE STUDY 92
2.4 DBMR TRIPOD DATA VALIDATION MODEL 93
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96
2.6 MULTIVARIATE MODELLING 97
2.7 TYPE LIFELINE CURVE 97
2.8 DBMR MARKET POSITION GRID 98
2.9 VENDOR SHARE ANALYSIS 100
2.10 MARKET END-USER COVERAGE GRID 101
2.11 SECONDARY SOURCES 102
2.12 ASSUMPTIONS 102
3 EXECUTIVE SUMMARY 103
4 PREMIUM INSIGHT 106
4.1 PESTEL ANALYSIS 107
4.2 PORTER’S FIVE FORCES 108
5 EPIDEMIOLOGY 109
6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA 110
7 INDUSTRY INSIGHTS: 111
8 NORTH AMERICA DYSPEPSIA DRUG MARKET, REGULATION 112
9 MARKET OVERVIEW 115
9.1 DRIVERS 117
9.1.1 INCREASING PREVALENCE OF DYSPEPSIA 117
9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE 117
9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS 118
9.2 RESTRAINTS 119
9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA 119
9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES 120
9.3 OPPORTUNITIES 120
9.3.1 GROWING AGING POPULATION 120
9.3.2 RISE IN THE DRUG APPROVAL 121
9.4 CHALLENGES 122
9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION 122
9.4.2 STRINGENT REGULATIONS 122
10 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TYPE 123
10.1 OVERVIEW 124
10.2 NON-ULCER DYSPEPSIA 127
10.3 ORGANIC DYSPEPSIA 127
10.4 DRUG INDUCED DYSPEPSIA 128
10.5 OTHERS 129
11 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE 130
11.1 OVERVIEW 131
11.2 MEDICATION 134
11.2.1 DRUGS 135
11.2.1.1 ANTACIDS 135
11.2.1.1.1 PROTON PUMP INHIBITORS (PPI’S) 135
11.2.1.1.1.1 OMEPRAZOLE 136
11.2.1.1.1.2 LANSOPRAZOLE 136
11.2.1.1.1.3 ESOMEPRAZOLE 136
11.2.1.1.1.4 OTHERS 136
11.2.1.1.2 H2 BLOCKERS 136
11.2.1.1.2.1 CIMETIDINE 137
11.2.1.1.2.2 FAMOTIDINE 137
11.2.1.1.2.3 NIZATIDINE 137
11.2.1.1.2.4 RANITIDINE 137
11.2.1.1.2.5 OTHERS 137
11.2.1.2 GASTRIC PROKINETIC GENDERNTS 137
11.2.1.2.1 MOSAPRIDE CITRATE 138
11.2.1.2.2 METOCLOPRAMIDE 138
11.2.1.2.3 CISAPRIDE 138
11.2.1.2.4 ITOPRIDE HYDROCHLORIDE 138
11.2.1.2.5 DOMPERIDONE 138
11.2.1.2.6 OTHERS 139
11.2.1.3 ANTIBIOTICS 139
11.2.1.3.1 REFAXIMIN 139
11.2.1.3.2 AMOXICILLIN 139
11.2.1.3.3 CLARITHROMYCIN 139
11.2.1.3.4 METRONIDAZOLE 140
11.2.1.3.5 LEVOFLOXACIN 140
11.2.1.3.6 TETRACYCLINE 140
11.2.1.3.7 OTHERS 140
11.2.1.4 OTHERS 140
11.2.2 NON- DRUGS 140
11.2.2.1 PROBIOTICS 140
11.2.2.1.1 LACTOBACILLUS 141
11.2.2.1.2 BIFIDOBACTERIUM 141
11.2.2.1.3 BACILLUS 141
11.2.2.1.4 STREPTOCOCCUS 141
11.2.2.1.5 OTHERS 141
11.2.2.2 PREBIOTICS 141
11.3 SURGERY 142
12 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE 143
12.1 OVERVIEW 144
12.2 GENERIC 147
12.3 BRANDED 148
13 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION 149
13.1 OVERVIEW 150
13.2 WITHOUT PRESCRIPTION DRUGS 153
13.3 PRESCRIPTION DRUGS 154
14 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION 155
14.1 OVERVIEW 156
14.2 ORAL 159
14.2.1 TABLETS 159
14.2.2 CAPSULES 160
14.3 INJECTABLE 160
15 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY GENDER 161
15.1 OVERVIEW 162
15.2 FEMALE 165
15.2.1 30-50 YEARS 166
15.2.2 MORE THAN 50 YEARS 166
15.2.3 AGE LESS THAN 30 166
15.3 MALE 166
15.3.1 30-50 YEARS 167
15.3.2 MORE THAN 50 YEARS 167
15.3.3 AGE LESS THAN 30 167
16 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY END USER 168
16.1 OVERVIEW 169
16.2 HOSPITALS 172
16.2.1 TYPE 172
16.2.1.1 PUBLIC 173
16.2.1.2 PRIVATE 173
16.2.2 TIER 173
16.2.2.1 TIER 3 173
16.2.2.2 TIER 2 173
16.2.2.3 TEIR 1 173
16.3 CLINICS 173
16.4 HOMECARE SETTINGS 174
16.5 SPECIALTY CLINICS 175
16.6 AMBULATORY CENTERS 176
16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 176
16.8 OTHERS 177
17 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL 178
17.1 OVERVIEW 179
17.2 RETAIL SALES 182
17.2.1 REATIL PHARMACY 183
17.2.2 HOSPITAL PHARMACY 183
17.2.3 ONLINE PHARMACY 183
17.3 DIRECT TENDER 183
18 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY REGION 184
18.1 NORTH AMERICA 185
18.1.1 U.S. 198
18.1.2 CANADA 206
18.1.3 MEXICO 215
19 NORTH AMERICA DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE 224
19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 224
20 SWOT ANALYSIS 225
21 NORTH AMERICA DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS 226
21.1 SANOFI 226
21.1.1 COMPANY SNAPSHOT 226
21.1.2 REVENUE ANALYSIS 226
21.1.3 COMPANY SHARE ANALYSIS 227
21.1.4 PRODUCT PORTFOLIO 227
21.1.5 RECENT DEVELOPMENT 227
21.2 LUPIN 228
21.2.1 COMPANY SNAPSHOT 228
21.2.2 REVENUE ANALYSIS 228
21.2.3 COMPANY SHARE ANALYSIS 229
21.2.4 PRODUCT PORTFOLIO 229
21.2.5 RECENT DEVELOPMENTS 229
21.3 MANKIND PHARMA 230
21.3.1 COMPANY SNAPSHOT 230
21.3.2 REVENUE ANALYSIS 230
21.3.3 COMPANY SHARE ANALYSIS 231
21.3.4 PRODUCT PORTFOLIO 231
21.3.5 RECENT DEVELOPMENT 231
21.4 ASTRAZENECA 232
21.4.1 COMPANY SNAPSHOT 232
21.4.2 REVENUE ANALYSIS 232
21.4.3 COMPANY SHARE ANALYSIS 233
21.4.4 PRODUCT PORTFOLIO 233
21.4.5 RECENT DEVELOPMENT 233
21.5 BAYER AG 234
21.5.1 COMPANY SNAPSHOT 234
21.5.2 REVENUE ANALYSIS 234
21.5.3 COMPANY SHARE ANALYSIS 235
21.5.4 PRODUCT PORTFOLIO 235
21.5.5 RECENT DEVELOPMENT 235
21.6 ABBOTT 236
21.6.1 COMPANY SNAPSHOT 236
21.6.2 REVENUE ANALYSIS 236
21.6.3 PRODUCT PORTFOLIO 237
21.6.4 RECENT DEVELOPMENT 237
21.7 ANI PHARMACEUTICALS, INC. 238
21.7.1 COMPANY SNAPSHOT 238
21.7.2 REVENUE ANALYSIS 238
21.7.3 PRODUCT PORTFOLIO 239
21.7.4 RECENT DEVELOPMENT 239
21.8 AOSAIKANG PHARMACEUTICAL CO., LTD. 240
21.8.1 COMPANY SNAPSHOT 240
21.8.2 REVENUE ANALYSIS 240
21.8.3 PRODUCT PORTFOLIO 241
21.8.4 RECENT DEVELOPMENT 241
21.9 ASTERISK LABORATORIES (I) PVT. LTD 242
21.9.1 COMPANY SNAPSHOT 242
21.9.2 PRODUCT PORTFOLIO 242
21.9.3 RECENT DEVELOPMENT 242
21.10 CADILA PHARMACEUTICALS 243
21.10.1 COMPANY SNAPSHOT 243
21.10.2 REVENUE ANALYSIS 243
21.10.3 COMPANY SHARE ANALYSIS 244
21.10.4 PRODUCT PORTFOLIO 244
21.10.5 RECENT DEVELOPMENT 244
21.11 HANMI PHARM. CO., LTD. 245
21.11.1 COMPANY SNAPSHOT 245
21.11.2 REVENUE ANALYSIS 245
21.11.3 PRODUCT PORTFOLIO 246
21.11.4 RECENT DEVELOPMENT 246
21.12 MCNEIL CONSUMER PHARMACEUTICALS CO. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 247
21.12.1 COMPANY SNAPSHOT 247
21.12.2 REVENUE ANALYSIS 247
21.12.3 PRODUCT PORTFOLIO 248
21.12.4 RECENT DEVELOPMENT 248
21.13 OTSUKA PHARMACEUTICAL CO., LTD. 249
21.13.1 COMPANY SNAPSHOT 249
21.13.2 REVENUE ANALYSIS 249
21.13.3 PRODUCT PORTFOLIO 250
21.13.4 RECENT DEVELOPMENT 250
21.14 PERRIGO COMPANY PLC 251
21.14.1 COMPANY SNAPSHOT 251
21.14.2 REVENUE ANALYSIS 251
21.14.3 PRODUCT PORTFOLIO 252
21.14.4 RECENT DEVELOPMENT 252
21.15 PRESTIGE CONSUMER HEALTHCARE, INC. 253
21.15.1 COMPANY SNAPSHOT 253
21.15.2 REVENUE ANALYSIS 253
21.15.3 PRODUCT PORTFOLIO 254
21.15.4 RECENT DEVELOPMENT 254
21.16 PROCTER & GAMBLE 255
21.16.1 COMPANY SNAPSHOT 255
21.16.2 REVENUE ANALYSIS 255
21.16.3 PRODUCT PORTFOLIO 256
21.16.4 RECENT DEVELOPMENT 256
21.17 RECKITT BENCKISER. 257
21.17.1 COMPANY SNAPSHOT 257
21.17.2 REVENUE ANALYSIS 257
21.17.3 PRODUCT PORTFOLIO 258
21.17.4 RECENT DEVELOPMENT 258

　

ページTOPに戻る


　

Summary

North America dyspepsia drug market is expected to reach USD 539,245.09 thousand by 2030 from USD 351,924.80 thousand in 2022, growing at a CAGR of 5.6% during the forecast period of 2023 to 2030.

Market Segmentation:
North America Dyspepsia Drug Market, By Type (Organic Dyspepsia, Non-Ulcer Dyspepsia, Drug Induced Dyspepsia, and Others), Treatment Type (Medication and Surgery), Drug Type (Branded and Generic), Prescription (Without Prescription Drugs and Prescription Drugs), Route of Administration (Oral and Injectable), Gender (Male and Female), End-User (Hospitals, Clinics, Homecare settings, Specialty Clinics, Ambulatory Surgical Centers, Academic and Government Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (U.S., Canada, Mexico,) - Industry Trends and Forecast to 2030


Overview of North America Dyspepsia Drug Market Dynamics:

Driver
• Increasing prevalence of dyspepsia

Restrain

• Possible side effects of the drugs used for dyspepsia

Opportunity

• Growing aging population


Market Players:

Some of the key market players operating in the North America dyspepsia drug market are listed below:

• Abbott
• Bayer AG
• Cadila Pharmaceuticals
• Sanofi
• Lupin
• Perrigo Company plc
• Reckitt Benckiser
• AstraZeneca
• Procter & Gamble
• Otsuka Pharmaceutical Co., Ltd.
• Others



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE NORTH AMERICA DYSPEPSIA DRUG MARKET 84
1.4 CURRENCY AND PRICING 86
1.5 LIMITATIONS 86
1.6 MARKETS COVERED 86
2 MARKET SEGMENTATION 90
2.1 MARKETS COVERED 90
2.2 GEOGRAPHICAL SCOPE 91
2.3 YEARS CONSIDERED FOR THE STUDY 92
2.4 DBMR TRIPOD DATA VALIDATION MODEL 93
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96
2.6 MULTIVARIATE MODELLING 97
2.7 TYPE LIFELINE CURVE 97
2.8 DBMR MARKET POSITION GRID 98
2.9 VENDOR SHARE ANALYSIS 100
2.10 MARKET END-USER COVERAGE GRID 101
2.11 SECONDARY SOURCES 102
2.12 ASSUMPTIONS 102
3 EXECUTIVE SUMMARY 103
4 PREMIUM INSIGHT 106
4.1 PESTEL ANALYSIS 107
4.2 PORTER’S FIVE FORCES 108
5 EPIDEMIOLOGY 109
6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA 110
7 INDUSTRY INSIGHTS: 111
8 NORTH AMERICA DYSPEPSIA DRUG MARKET, REGULATION 112
9 MARKET OVERVIEW 115
9.1 DRIVERS 117
9.1.1 INCREASING PREVALENCE OF DYSPEPSIA 117
9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE 117
9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS 118
9.2 RESTRAINTS 119
9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA 119
9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES 120
9.3 OPPORTUNITIES 120
9.3.1 GROWING AGING POPULATION 120
9.3.2 RISE IN THE DRUG APPROVAL 121
9.4 CHALLENGES 122
9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION 122
9.4.2 STRINGENT REGULATIONS 122
10 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TYPE 123
10.1 OVERVIEW 124
10.2 NON-ULCER DYSPEPSIA 127
10.3 ORGANIC DYSPEPSIA 127
10.4 DRUG INDUCED DYSPEPSIA 128
10.5 OTHERS 129
11 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE 130
11.1 OVERVIEW 131
11.2 MEDICATION 134
11.2.1 DRUGS 135
11.2.1.1 ANTACIDS 135
11.2.1.1.1 PROTON PUMP INHIBITORS (PPI’S) 135
11.2.1.1.1.1 OMEPRAZOLE 136
11.2.1.1.1.2 LANSOPRAZOLE 136
11.2.1.1.1.3 ESOMEPRAZOLE 136
11.2.1.1.1.4 OTHERS 136
11.2.1.1.2 H2 BLOCKERS 136
11.2.1.1.2.1 CIMETIDINE 137
11.2.1.1.2.2 FAMOTIDINE 137
11.2.1.1.2.3 NIZATIDINE 137
11.2.1.1.2.4 RANITIDINE 137
11.2.1.1.2.5 OTHERS 137
11.2.1.2 GASTRIC PROKINETIC GENDERNTS 137
11.2.1.2.1 MOSAPRIDE CITRATE 138
11.2.1.2.2 METOCLOPRAMIDE 138
11.2.1.2.3 CISAPRIDE 138
11.2.1.2.4 ITOPRIDE HYDROCHLORIDE 138
11.2.1.2.5 DOMPERIDONE 138
11.2.1.2.6 OTHERS 139
11.2.1.3 ANTIBIOTICS 139
11.2.1.3.1 REFAXIMIN 139
11.2.1.3.2 AMOXICILLIN 139
11.2.1.3.3 CLARITHROMYCIN 139
11.2.1.3.4 METRONIDAZOLE 140
11.2.1.3.5 LEVOFLOXACIN 140
11.2.1.3.6 TETRACYCLINE 140
11.2.1.3.7 OTHERS 140
11.2.1.4 OTHERS 140
11.2.2 NON- DRUGS 140
11.2.2.1 PROBIOTICS 140
11.2.2.1.1 LACTOBACILLUS 141
11.2.2.1.2 BIFIDOBACTERIUM 141
11.2.2.1.3 BACILLUS 141
11.2.2.1.4 STREPTOCOCCUS 141
11.2.2.1.5 OTHERS 141
11.2.2.2 PREBIOTICS 141
11.3 SURGERY 142
12 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE 143
12.1 OVERVIEW 144
12.2 GENERIC 147
12.3 BRANDED 148
13 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION 149
13.1 OVERVIEW 150
13.2 WITHOUT PRESCRIPTION DRUGS 153
13.3 PRESCRIPTION DRUGS 154
14 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION 155
14.1 OVERVIEW 156
14.2 ORAL 159
14.2.1 TABLETS 159
14.2.2 CAPSULES 160
14.3 INJECTABLE 160
15 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY GENDER 161
15.1 OVERVIEW 162
15.2 FEMALE 165
15.2.1 30-50 YEARS 166
15.2.2 MORE THAN 50 YEARS 166
15.2.3 AGE LESS THAN 30 166
15.3 MALE 166
15.3.1 30-50 YEARS 167
15.3.2 MORE THAN 50 YEARS 167
15.3.3 AGE LESS THAN 30 167
16 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY END USER 168
16.1 OVERVIEW 169
16.2 HOSPITALS 172
16.2.1 TYPE 172
16.2.1.1 PUBLIC 173
16.2.1.2 PRIVATE 173
16.2.2 TIER 173
16.2.2.1 TIER 3 173
16.2.2.2 TIER 2 173
16.2.2.3 TEIR 1 173
16.3 CLINICS 173
16.4 HOMECARE SETTINGS 174
16.5 SPECIALTY CLINICS 175
16.6 AMBULATORY CENTERS 176
16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 176
16.8 OTHERS 177
17 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL 178
17.1 OVERVIEW 179
17.2 RETAIL SALES 182
17.2.1 REATIL PHARMACY 183
17.2.2 HOSPITAL PHARMACY 183
17.2.3 ONLINE PHARMACY 183
17.3 DIRECT TENDER 183
18 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY REGION 184
18.1 NORTH AMERICA 185
18.1.1 U.S. 198
18.1.2 CANADA 206
18.1.3 MEXICO 215
19 NORTH AMERICA DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE 224
19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 224
20 SWOT ANALYSIS 225
21 NORTH AMERICA DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS 226
21.1 SANOFI 226
21.1.1 COMPANY SNAPSHOT 226
21.1.2 REVENUE ANALYSIS 226
21.1.3 COMPANY SHARE ANALYSIS 227
21.1.4 PRODUCT PORTFOLIO 227
21.1.5 RECENT DEVELOPMENT 227
21.2 LUPIN 228
21.2.1 COMPANY SNAPSHOT 228
21.2.2 REVENUE ANALYSIS 228
21.2.3 COMPANY SHARE ANALYSIS 229
21.2.4 PRODUCT PORTFOLIO 229
21.2.5 RECENT DEVELOPMENTS 229
21.3 MANKIND PHARMA 230
21.3.1 COMPANY SNAPSHOT 230
21.3.2 REVENUE ANALYSIS 230
21.3.3 COMPANY SHARE ANALYSIS 231
21.3.4 PRODUCT PORTFOLIO 231
21.3.5 RECENT DEVELOPMENT 231
21.4 ASTRAZENECA 232
21.4.1 COMPANY SNAPSHOT 232
21.4.2 REVENUE ANALYSIS 232
21.4.3 COMPANY SHARE ANALYSIS 233
21.4.4 PRODUCT PORTFOLIO 233
21.4.5 RECENT DEVELOPMENT 233
21.5 BAYER AG 234
21.5.1 COMPANY SNAPSHOT 234
21.5.2 REVENUE ANALYSIS 234
21.5.3 COMPANY SHARE ANALYSIS 235
21.5.4 PRODUCT PORTFOLIO 235
21.5.5 RECENT DEVELOPMENT 235
21.6 ABBOTT 236
21.6.1 COMPANY SNAPSHOT 236
21.6.2 REVENUE ANALYSIS 236
21.6.3 PRODUCT PORTFOLIO 237
21.6.4 RECENT DEVELOPMENT 237
21.7 ANI PHARMACEUTICALS, INC. 238
21.7.1 COMPANY SNAPSHOT 238
21.7.2 REVENUE ANALYSIS 238
21.7.3 PRODUCT PORTFOLIO 239
21.7.4 RECENT DEVELOPMENT 239
21.8 AOSAIKANG PHARMACEUTICAL CO., LTD. 240
21.8.1 COMPANY SNAPSHOT 240
21.8.2 REVENUE ANALYSIS 240
21.8.3 PRODUCT PORTFOLIO 241
21.8.4 RECENT DEVELOPMENT 241
21.9 ASTERISK LABORATORIES (I) PVT. LTD 242
21.9.1 COMPANY SNAPSHOT 242
21.9.2 PRODUCT PORTFOLIO 242
21.9.3 RECENT DEVELOPMENT 242
21.10 CADILA PHARMACEUTICALS 243
21.10.1 COMPANY SNAPSHOT 243
21.10.2 REVENUE ANALYSIS 243
21.10.3 COMPANY SHARE ANALYSIS 244
21.10.4 PRODUCT PORTFOLIO 244
21.10.5 RECENT DEVELOPMENT 244
21.11 HANMI PHARM. CO., LTD. 245
21.11.1 COMPANY SNAPSHOT 245
21.11.2 REVENUE ANALYSIS 245
21.11.3 PRODUCT PORTFOLIO 246
21.11.4 RECENT DEVELOPMENT 246
21.12 MCNEIL CONSUMER PHARMACEUTICALS CO. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 247
21.12.1 COMPANY SNAPSHOT 247
21.12.2 REVENUE ANALYSIS 247
21.12.3 PRODUCT PORTFOLIO 248
21.12.4 RECENT DEVELOPMENT 248
21.13 OTSUKA PHARMACEUTICAL CO., LTD. 249
21.13.1 COMPANY SNAPSHOT 249
21.13.2 REVENUE ANALYSIS 249
21.13.3 PRODUCT PORTFOLIO 250
21.13.4 RECENT DEVELOPMENT 250
21.14 PERRIGO COMPANY PLC 251
21.14.1 COMPANY SNAPSHOT 251
21.14.2 REVENUE ANALYSIS 251
21.14.3 PRODUCT PORTFOLIO 252
21.14.4 RECENT DEVELOPMENT 252
21.15 PRESTIGE CONSUMER HEALTHCARE, INC. 253
21.15.1 COMPANY SNAPSHOT 253
21.15.2 REVENUE ANALYSIS 253
21.15.3 PRODUCT PORTFOLIO 254
21.15.4 RECENT DEVELOPMENT 254
21.16 PROCTER & GAMBLE 255
21.16.1 COMPANY SNAPSHOT 255
21.16.2 REVENUE ANALYSIS 255
21.16.3 PRODUCT PORTFOLIO 256
21.16.4 RECENT DEVELOPMENT 256
21.17 RECKITT BENCKISER. 257
21.17.1 COMPANY SNAPSHOT 257
21.17.2 REVENUE ANALYSIS 257
21.17.3 PRODUCT PORTFOLIO 258
21.17.4 RECENT DEVELOPMENT 258

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

Data Bridge Market Research社の医薬分野での最新刊レポート

本レポートと同じKEY WORD（drug）の最新刊レポート


よくあるご質問


Data Bridge Market Research社はどのような調査会社ですか?


データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/20　10:26

155.91 円

165.77 円

200.60 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.